2 Dec 2019 09:00
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Grant of Share Options and Notification of Director / PDMR Dealings
Omega Diagnostics (AIM: ODX), the medical diagnostics company focused on CD4, food intolerance and allergy testing, announces that the Group's Remuneration Committee and the Board have approved the grant of 500,000 options ("New Options") over ordinary shares of 4 pence each ("Ordinary Shares") to Jeremy Millard, Non-Executive Director, pursuant to the Group's existing share option schemes.
All New Options were granted with an exercise price of 10 pence each, being the closing middle market price on 29 November 2019. The New Options will vest over three years, one third vesting on each anniversary of the grant date.
The grant of 500,000 New Options equates to 0.33 per cent. of the Group's current issued share capital. In total, 9,420,406 options are now under grant but not exercised, which equates to 6.3 per cent. of the Group's current issued share capital.
The FCA notification, made in accordance with the requirements of the EU Market Abuse Regulation is appended below.
The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.
Contacts:
Omega Diagnostics Group PLC | Tel: 01259 763 030 |
Bill Rhodes, Interim Non-Executive Chairman Colin King, Chief Executive | www.omegadiagnostics.com |
Kieron Harbinson, Group Finance Director |
|
| Mob: 07740 084452 |
|
|
finnCap Ltd | Tel: 020 7220 0500 |
Geoff Nash/Hannah Boros (Corporate Finance) |
|
Camille Gochez (Corporate Broking) |
|
|
|
Walbrook PR Limited | Tel: 020 7933 8780 or omega@walbrookpr.com |
Paul McManus | Mob: 07980 541 893 |
Lianne Cawthorne | Mob: 07584 391 303 |
| Details of the person discharging managerial responsibilities/person closely associated | |||||||
a) | Name: | Jeremy Millard | ||||||
| Reason for the notification | |||||||
a) | Position/status: | Non-Executive Director | ||||||
b) | Initial notification/Amendment: | Initial Notification | ||||||
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a) | Name: | Omega Diagnostics Group Plc | ||||||
b) | LEI: | 2138007U9P4BTZTYIR92 | ||||||
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary Shares of 0.5 pence each GB00B1VCP282
| ||||||
b) | Nature of the transaction: | Grant of options over Ordinary Shares | ||||||
c) | Price(s) and volume(s): |
| ||||||
d) | Aggregated information: ·; Aggregated volume: ·; Price: | Single transaction as in 4 c) above
| ||||||
e) | Date of the transaction: | 2 December 2019 | ||||||
f) | Place of the transaction: | n/a | ||||||